SI9300219B - Synergistic combination of a substanse with gastric acid secretion inhibiting effect and non-acidoresistent antibiotic - Google Patents
Synergistic combination of a substanse with gastric acid secretion inhibiting effect and non-acidoresistent antibiotic Download PDFInfo
- Publication number
- SI9300219B SI9300219B SI9300219A SI9300219A SI9300219B SI 9300219 B SI9300219 B SI 9300219B SI 9300219 A SI9300219 A SI 9300219A SI 9300219 A SI9300219 A SI 9300219A SI 9300219 B SI9300219 B SI 9300219B
- Authority
- SI
- Slovenia
- Prior art keywords
- combination
- acid
- combination according
- antibiotic
- gastric acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06066—Needles, e.g. needle tip configurations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30092—Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
- A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
- A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
- A61F2210/0047—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply heated by light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1 Patentni zahtevki 1. Kombinacija substance, ki inhibira izločanje želodčne kisline in tako poviša pH v želodcu, in v kislini razgradljive protibakterijske spojine, pri čemer je izključena samo kombinacija obeh komponent omeprazola in klaritromicina.
2. Kombinacija po zahtevku 1, označena s tem, daje substanca, ki inhibira izločanje želodčne kisline, inhibitor protonske črpalke.
3. Kombinacija po zahtevku 2, označena s tem, daje inhibitor protonske črpalke 5- metoksi-2- {[(4-metoksi-3,5 -dimetil-2-piridinil)metil]sulfinil} -1 H-benzimidazol ali njegova farmacevtsko sprejemljiva sol.
4. Kombinacija po zahtevku 1, označena s tem, da učinkuje na gastritis in peptični ulkus, katerih povzročitelji so mikroorganizmi.
5. Kombinacija po zahtevku 1, označena s tem, da učinkuje na gastritis in peptični ulkus, ki ga povzroča Helicobacter pylori.
6. Kombinacija po zahtevku 1, označena s tem, da je v kislini neobstojna protibakterijska spojina benzilpenicilin.
7. Kombinacija po kateremkoli od zahtevkov 1 do 6, označena s tem, da je v kislini razgradljiva protibakterijska spojina antibiotik v obliki šibke baze.
8. Kombinacija po zahtevku 7, označena s tem, da je antibiotik v obliki šibke baze eritromicin v obliki šibke baze.
9. Kombinacija po zahtevku 7, označena s tem, daje antibiotik klaritromicin. 2
10. Kombinacija po zahtevku 1, označena s tem, daje namenjena izdelavi zdravila za zdravljenje gastritisa in peptičnega ulkusa, ki ga povzroča Helicobacter pylori.
11. Uporaba kombinacije substance, ki inhibira izločanje želodčne kisline, ki poviša pH v želodcu, in v kislini razgradljive protibakterijske spojine za pripravo zdravila pri zdravljenju gastritisa in peptičnega ulkusa, ki ga povzroča Helicobacter pylori.
12. Farmacevtski pripravek za uporabo pri zdravljenju gastritisa in peptičnega ulkusa, ki ga povzročijo infekcije s Helicobacter pylori, kjer sta aktivni sestavini substanca, ki inhibira izločanje želodčne kisline, ki poviša pH v želodcu, in v kislini razgradljiva protibakterijska spojina, pri čemer je izključena samo kombinacija obeh komponent omeprazola in klaritromicina.
13. Postopek za pripravo farmacevtskega pripravka po zahtevku 12, označen s tem, da substanco, ki inhibira izločanje želodčne kisline, ki poviša pH v želodcu, vdelamo v isti pripravek kot v kislini razgradljivo protibakterijsko spojin. 22724-X-01-mn
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9201297A SE9201297D0 (sv) | 1992-04-24 | 1992-04-24 | Synergistic combination |
SE9300029A SE9300029D0 (sv) | 1993-01-08 | 1993-01-08 | Synergistic combination ii |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9300219A SI9300219A (sl) | 1993-12-31 |
SI9300219B true SI9300219B (en) | 2001-12-31 |
Family
ID=26661401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9300219A SI9300219B (en) | 1992-04-24 | 1993-04-23 | Synergistic combination of a substanse with gastric acid secretion inhibiting effect and non-acidoresistent antibiotic |
Country Status (39)
Country | Link |
---|---|
US (3) | US5599794A (sl) |
EP (2) | EP0637241B1 (sl) |
JP (1) | JPH07505901A (sl) |
KR (1) | KR100340165B1 (sl) |
CN (1) | CN1041798C (sl) |
AP (1) | AP466A (sl) |
AT (1) | ATE194286T1 (sl) |
AU (1) | AU669903B2 (sl) |
CA (1) | CA2133762C (sl) |
CZ (1) | CZ291201B6 (sl) |
DE (2) | DE69328967T2 (sl) |
DK (1) | DK0637241T3 (sl) |
DZ (1) | DZ1683A1 (sl) |
EE (1) | EE03149B1 (sl) |
ES (1) | ES2100135T3 (sl) |
FI (1) | FI944953A (sl) |
GR (2) | GR970300011T1 (sl) |
HK (1) | HK1008296A1 (sl) |
HR (1) | HRP930755B1 (sl) |
HU (1) | HUT71225A (sl) |
IL (1) | IL105155A (sl) |
IS (1) | IS3990A (sl) |
LV (1) | LV12625B (sl) |
MA (1) | MA22878A1 (sl) |
MY (1) | MY121189A (sl) |
NO (1) | NO314288B1 (sl) |
NZ (1) | NZ252759A (sl) |
PL (1) | PL173485B1 (sl) |
PT (1) | PT637241E (sl) |
RO (1) | RO115780B1 (sl) |
RU (1) | RU2143899C1 (sl) |
SG (1) | SG52485A1 (sl) |
SI (1) | SI9300219B (sl) |
SK (1) | SK282420B6 (sl) |
TN (1) | TNSN93040A1 (sl) |
TW (1) | TW276996B (sl) |
UA (1) | UA43830C2 (sl) |
WO (1) | WO1993021920A1 (sl) |
YU (1) | YU49091B (sl) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW420610B (en) * | 1994-04-07 | 2001-02-01 | Pfizer | A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
CN1061232C (zh) * | 1996-04-12 | 2001-01-31 | 马理国 | 一种治疗胃炎、溃疡的药物组合物 |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
DE69827392T2 (de) * | 1997-07-25 | 2005-10-27 | Altana Pharma Ag | Protonenpumpenhemmer als kombinationstherapeutika mit antibakteriell wirkenden substanzen |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6117868A (en) * | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
CA2362930C (en) * | 1999-02-26 | 2010-10-05 | Nitromed, Inc. | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US7365047B1 (en) * | 1999-09-28 | 2008-04-29 | The Regents Of The University Of California | Use of pentagastrin to inhibit gastric acid secretion or as a diuretic |
US20020004502A1 (en) * | 2000-01-05 | 2002-01-10 | Redmond H. Paul | Treatment of inflammatory bowel disease |
US6787342B2 (en) | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
AU2578701A (en) * | 2000-02-29 | 2001-09-12 | Teva Pharma | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
EP1133987A1 (en) * | 2000-03-09 | 2001-09-19 | Ian Whitcroft | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
CA2413923A1 (en) * | 2000-03-09 | 2001-09-13 | Andrew Ilchyshyn | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
AU6381201A (en) * | 2000-03-28 | 2001-10-08 | Biochemie Gmbh | Granulated particles with masked taste |
SE0002476D0 (sv) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
US6544556B1 (en) * | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
AU2001296908A1 (en) * | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
SE0103695D0 (sv) | 2001-11-07 | 2001-11-07 | Thomas Boren | A novel non-antibiotic strategy against OGIP infections based on a cereal product |
WO2003063927A2 (en) * | 2001-11-16 | 2003-08-07 | Eisai Co. Ltd | Compositions and methods to treat gastrointestinal disorders |
WO2003063840A2 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
JP4634144B2 (ja) * | 2002-08-01 | 2011-02-16 | ニコックス エスエー | ニトロソ化プロトンポンプ阻害剤、組成物および使用方法 |
EP1485373A1 (en) * | 2003-02-05 | 2004-12-15 | Teva Pharmaceutical Industries Limited | Method of stabilizing lansoprazole |
CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US20040185092A1 (en) * | 2003-03-18 | 2004-09-23 | Yih Ming Hsiao | Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use |
WO2005007117A2 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
US20050037070A1 (en) * | 2003-07-18 | 2005-02-17 | Santarus, Inc. | Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20060194748A1 (en) * | 2005-02-28 | 2006-08-31 | National University Corporation Nagoya University | Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same |
WO2007070164A1 (en) * | 2005-10-19 | 2007-06-21 | The Curators Of The University Of Missouri | Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
EP2068841B1 (en) | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
EP2086543A2 (en) | 2006-10-27 | 2009-08-12 | The Curators of the University of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10869690B2 (en) * | 2017-06-29 | 2020-12-22 | Ethicon Llc | Trocar obturator with transverse needle ports |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85472A (en) * | 1987-03-09 | 1991-06-30 | Procter & Gamble | Pharmaceutical compositions for treating gastrointestinal disorders |
JP2694361B2 (ja) * | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
DK0382489T3 (da) * | 1989-02-10 | 1995-01-16 | Takeda Chemical Industries Ltd | Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf |
GB9018603D0 (en) * | 1990-08-24 | 1990-10-10 | Smith Kline French Lab | Compositions |
ES2169022T3 (es) * | 1990-09-14 | 2002-07-01 | Byk Gulden Lomberg Chem Fab | Utilizacion de derivados de (piridil-metil-sulfinil)-1-h-bencimidazol para el tratamiento de enfermedades provocadas por helicobacter. |
-
1993
- 1993-03-24 IL IL10515593A patent/IL105155A/en active IP Right Review Request
- 1993-03-24 IS IS3990A patent/IS3990A/is unknown
- 1993-03-24 TW TW082102192A patent/TW276996B/zh active
- 1993-04-02 HR HR930755A patent/HRP930755B1/xx not_active IP Right Cessation
- 1993-04-07 DZ DZ930044A patent/DZ1683A1/fr active
- 1993-04-15 AP APAP/P/1993/000518A patent/AP466A/en active
- 1993-04-20 RO RO94-01707A patent/RO115780B1/ro unknown
- 1993-04-20 SG SG1996005136A patent/SG52485A1/en unknown
- 1993-04-20 UA UA94105962A patent/UA43830C2/uk unknown
- 1993-04-20 RU RU94045926A patent/RU2143899C1/ru not_active IP Right Cessation
- 1993-04-20 CA CA002133762A patent/CA2133762C/en not_active Expired - Lifetime
- 1993-04-20 SK SK1275-94A patent/SK282420B6/sk not_active IP Right Cessation
- 1993-04-20 AU AU42737/93A patent/AU669903B2/en not_active Ceased
- 1993-04-20 DE DE69328967T patent/DE69328967T2/de not_active Revoked
- 1993-04-20 CZ CZ19942593A patent/CZ291201B6/cs not_active IP Right Cessation
- 1993-04-20 JP JP5519164A patent/JPH07505901A/ja active Pending
- 1993-04-20 HU HU9403069A patent/HUT71225A/hu not_active Application Discontinuation
- 1993-04-20 PL PL93305799A patent/PL173485B1/pl unknown
- 1993-04-20 NZ NZ252759A patent/NZ252759A/en not_active IP Right Cessation
- 1993-04-20 EP EP93912028A patent/EP0637241B1/en not_active Revoked
- 1993-04-20 DE DE0637241T patent/DE637241T1/de active Pending
- 1993-04-20 WO PCT/SE1993/000327 patent/WO1993021920A1/en not_active Application Discontinuation
- 1993-04-20 AT AT93912028T patent/ATE194286T1/de not_active IP Right Cessation
- 1993-04-20 DK DK93912028T patent/DK0637241T3/da active
- 1993-04-20 ES ES93912028T patent/ES2100135T3/es not_active Expired - Lifetime
- 1993-04-20 EP EP99108949A patent/EP0956857A3/en not_active Withdrawn
- 1993-04-20 PT PT93912028T patent/PT637241E/pt unknown
- 1993-04-21 YU YU27593A patent/YU49091B/sh unknown
- 1993-04-21 MA MA23171A patent/MA22878A1/fr unknown
- 1993-04-22 US US08/051,722 patent/US5599794A/en not_active Expired - Fee Related
- 1993-04-23 TN TNTNSN93040A patent/TNSN93040A1/fr unknown
- 1993-04-23 SI SI9300219A patent/SI9300219B/sl not_active IP Right Cessation
- 1993-04-23 MY MYPI93000749A patent/MY121189A/en unknown
- 1993-04-24 CN CN93105000A patent/CN1041798C/zh not_active Expired - Fee Related
-
1994
- 1994-10-21 FI FI944953A patent/FI944953A/fi not_active Application Discontinuation
- 1994-10-21 NO NO19944010A patent/NO314288B1/no unknown
- 1994-10-22 KR KR1019940703767A patent/KR100340165B1/ko not_active IP Right Cessation
- 1994-11-17 EE EE9400418A patent/EE03149B1/xx not_active IP Right Cessation
-
1995
- 1995-05-16 US US08/442,382 patent/US5633244A/en not_active Expired - Lifetime
- 1995-05-16 US US08/441,766 patent/US5629305A/en not_active Expired - Lifetime
-
1997
- 1997-05-30 GR GR970300011T patent/GR970300011T1/el unknown
-
1998
- 1998-07-17 HK HK98109224A patent/HK1008296A1/xx not_active IP Right Cessation
-
2000
- 2000-09-21 GR GR20000402159T patent/GR3034470T3/el not_active IP Right Cessation
- 2000-10-16 LV LVP-00-139A patent/LV12625B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9300219B (en) | Synergistic combination of a substanse with gastric acid secretion inhibiting effect and non-acidoresistent antibiotic | |
RU94045926A (ru) | Фармацевтическая композиция, способ ее получения и способ лечения | |
WO2000062783A3 (en) | Ketolide antibacterials | |
CA2005986A1 (en) | Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation | |
DE69424487D1 (de) | Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff | |
WO2000044761A3 (en) | Ketolide antibiotics | |
IT1262993B (it) | Complesso di bismuto citrato di ranitidina ed antibiotico, composizione che lo contiene e relativo metodo di produzione ed impiego | |
NO176305C (no) | Fremgangsmåte for fremstilling av orale legemiddelformer av pimobendan | |
WO2004096822A3 (en) | Pyridyl substituted ketolide antibiotics | |
DK1057828T3 (da) | Orale trovafloxacin-suspensioner | |
CA2500218A1 (en) | Drug absorptivity improving agent | |
DE60035355D1 (de) | Immunverstärkende verbindungen | |
EA016824B1 (ru) | Дозируемая форма, содержащая пантопразол магния в качестве активного ингредиента | |
CA2005980A1 (en) | Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation | |
WO2002032919A3 (en) | 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance | |
DE602004011946T2 (de) | Alkalisalze von protonenpumpen-hemmern | |
WO1992004898A1 (de) | Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen | |
KR950028771A (ko) | 헬리코박터 필로리감염증의 치료방법 | |
JO1768B1 (en) | A synergistic formula with an inhibitory effect of gastric acid secretion and an acid-degradable antibiotic | |
RU98102187A (ru) | Применение аллиламиновых производных, таких как тербинафин, в изготовлении лекарственного средства для лечения инфекции helicobacter pylori или ассоциированных заболеваний | |
FR2264558A1 (en) | Polymixin-methyl tetracycline salt antibiotics - active against Gram positive and negative bacteria, viruses and protozoa | |
TH13397A (th) | การรวมเข้าด้วยกันที่เสริมฤทธิ์กันของสารที่มีผลยับยั้ง การหลั่งกรดของกระเพาะอาหารและยาปฏิชีวนะ ที่สลายในกรด | |
TH16891A (th) | สูตรผสมที่ประกอบด้วยสารต่อต้านแบคทีเรียและสารต่อต้านแผลอัลเซอร์ | |
KR20010086235A (ko) | 상승작용이 있는 항균제 조성물, 그것을 함유하는 의약 및소화기질환 치료제, 그들의 제조법, 및 그에 관련된 제제 | |
TH15733B (th) | การรวมเข้าด้วยกันที่เสริมฤทธิ์กันของสารที่มีผลยับยั้ง การหลั่งกรดของกระเพาะอาหารและยาปฏิชีวนะ ที่สลายในกรด |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
KO00 | Lapse of patent |
Effective date: 20100113 |